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Abstract Hypobaric hypoxic brain injury results in ele-
vated peripheral S100B levels which may relate to blood–
brain barrier (BBB) dysfunction. A period of acclimatisa-
tion or dexamethasone prevents altitude-related illnesses
and this may involve attenuation of BBB compromise. We
hypothesised that both treatments would diminish the
S100B response (a measure of BBB dysfunction) on re-
ascent to the hypobaric hypoxia of high altitude, in com-
parison to an identical ascent completed 48 h earlier by the
same group. Twelve healthy volunteers, six of which were
prescribed dexamethasone, ascended Mt Fuji (summit
3700 m) and serial plasma S100B levels measured. The
S100B values reduced from a baseline 0.183 lg/l (95 % CI
0.083–0.283) to 0.145 lg/l (95 % CI 0.088–0.202) at high
altitude for the dexamethasone group (n = 6) and from
0.147 lg/l (95 % CI 0.022–0.272) to 0.133 lg/l (95 % CI
0.085–0.182) for the non-treated group (n = 6) [not sta-
tistically significant (p = 0.43 and p = 0.82) for the trea-
ted and non-treated groups respectively]. [These results
contrasted with the statistically significant increase during
the first ascent, S100B increasing from 0.108 lg/l (95 %
CI 0.092–0.125) to 0.216 lg/l (95 % CI 0.165–0.267) at
high altitude]. In conclusion, an increase in plasma S100B
was not observed in the second ascent and this may relate
to the effect of acclimatisation (or hypoxic pre-condition-
ing) on the BBB. An exercise stimulated elevation of
plasma S100B levels was also not observed during the
second ascent. The small sample size and wide confidence
intervals, however, precludes any statistically significant
conclusions and a larger study would be required to con-
firm these findings.
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Introduction
S100B is a 21 kDa dimeric calcium-binding protein pre-
dominantly found in brain astrocytes [1] which regulates a
variety of cellular functions [2]. There is an extensive body
of literature regarding clinical conditions that have been
associated with elevated S100B levels. A recent review [3]
describes S100B associations with psychiatric disorders
(schizophrenia, depression), sport (running, boxing, soc-
cer), tumours (melanoma), multiple sclerosis, Alzheimer’s
disease, cardiac disease, stroke and patients with traumatic
brain injury or multi-trauma in the absence of brain injury.
Peripheral S100B levels have also been noted to increase in
patients with other hypoxic conditions such as obstructive
sleep apnoea [4] and its postulated neuroprotective prop-
erties may also reflect increased expression secondary to
post-injury reparative processes [5, 6]. Despite this many
authors believe that peripheral S100B levels correlates with
blood–brain barrier (BBB) dysfunction [7–9]. That CSF-
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serum albumin quotient (QA) is considered to be the gold
standard for quantifying the extent of BBB dysfunction
[10] and good correlation with serum S100B levels have
been reported [9] provides further supportive data.
Although high-altitude related illnesses, such as acute
mountain sickness (AMS), are thought to result from a
multitude of processes, it is considered that blood–brain
barrier (BBB) disruption is a significant contributor [11,
12]. Elevated peripheral S100B levels have been confirmed
in volunteers at high altitude and this may reflect hypoxic
opening of the BBB [13–15]. Furthermore, the vascular
permeability factor vascular endothelial growth factor
(VEGF) affects BBB function by altering tight junctions
between endothelial cells and its increased expression in
hypoxic conditions has been confirmed in animal studies
[16] and mountaineers at high altitude [17]. The hypobaric
hypoxia associated with altitude gain may induce VEGF
release, a compromised BBB, cerebral vasogenic oedema
and elevation of peripheral S100B. MRI findings of mild
extracellular vasogenic oedema at simulated high altitude
has also been described, suggestive of BBB compromise
[18].
During the process of acclimatisation individuals exhibit
specific cerebral physiological adaptive responses to
reduced oxygen levels, such as increased cerebral blood
flow (CBF) [19] and intracranial pressure [11]. Improved
exercise tolerance, cognitive performance and symptoms of
AMS following 16 days at high altitude have been reported
[20]. Of more importance the latter group noted that after a
period at low altitude the reduced incidence of AMS per-
sisted upon re-ascent. Wu et al. [21] also reports improved
AMS scores during re-exposure to 4500 m following long
periods (up to 5 months) of low altitude, which correlated
with improved oxygen saturations and lower resting HR.
To our knowledge BBB dysfunction during re-exposure to
high altitude has not been previously investigated. We
hypothesised that the improvement in altitude related ill-
nesses following acclimatisation may result from a bene-
ficial effect on the BBB and this may correlate with
diminished S100B levels. Our first paper [14] served to
document two important stand-alone conclusions; that a
statistically significant elevation in plasma S100B occurs
with altitude but the S100B levels did not correlate with
AMS. This companion paper from the same individuals at
the same time points during the same ascent 48 h earlier
allows us to compare two S100B data sets and comment on
any possible effects of acclimatisation on S100B levels.
When the participants ascended Mt Fuji 48 h earlier (i.e.
the first ascent) they commenced at the same time of day,
carried the same amount of weight (batteries, dry ice,
medical equipment, etc.), took the same time interval to
complete the distances between bleed-points, stayed over-
night at the summit (exactly as per the second ascent) and
descended at the same rate. We therefore felt that the two
S100B data sets were comparable.
Dexamethasone is used for the prophylaxis and treat-
ment of AMS and high altitude cerebral edema (HACE)
[12] and this may involve attenuation of the BBB. The
exact mechanism is unclear, though may involve changes
in calcium-activated potassium channels [22] or reducing
tight junction [23] or VEGF expression [24, 25]. We fur-
ther hypothesised that volunteers prescribed dexametha-
sone would exhibit an additional reduction in S100B, in
comparison to both the first ascent and with those who did
not take dexamethasone in the second ascent. Studying the
release of S100B in subjects at high altitude comprises a
method of evaluating the effect of reversible hypoxic injury
on the human BBB. Brain imaging (MRI) has been used in
studies of simulated high altitude but clearly is not avail-
able to investigate the brain response at actual high alti-
tude. Insights into the molecular responses by the brain to
the hypobaric hypoxia of high altitude and re-exposure
may potentially provide support for the development of
novel therapeutic strategies for high attitude related ill-
nesses and other hypoxic brain injuries.
As an addendum, a potential confounding factor for any
such field study is the relationship between peripheral
S100B levels and strenuous exercise. A recent systematic
review [26] lists several studies confirming higher S100B
levels post-exercise compared to pre-exercise values but
also reports many studies which failed to confirm such a
relationship. Ascending to 3700 m involves significant
exertion and by comparing the two ascents we may also be
able to comment on the possible phenomenon of exercise
induced S100B elevation.
Method
Following consent 12 healthy volunteers (gender ratio 1:1,
age range 22–56) were recruited. The Lake Louise Ques-
tionnaire [27] and oxygen saturations (TuffSat, Datex
Ohmeda) were completed at each bleed point. AMS was
diagnosed when the participant experienced a headache
and one other symptom to yield a score of 4 or more. On
day 2 the group was driven to 1400 m, trekked to 2590 m
(second blood test), and continued to the overnight
accommodation at 3200 m. On day 3 we reached the
summit (3700 m), remained for 2–3 h (blood test) and
descended the mountain (blood test at 2590 m). Regular
fluid intake was ensured in order to prevent dehydration. In
summary, samples for S100B were taken at baseline (32 m
above sea level), at 2590, at 3700 and then again at 2590 m
during descent. The 12 subjects were randomly divided
into a dexamethasone (n = 6) and a non-dexamethasone
group (n = 6). The standard dose for the prevention or
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treatment of AMS was used (4 mg twice daily for 2 days
commencing at the beginning of the ascent).
At each bleed point 12 ml of venous blood (Li-Heparin
tubes) was centrifuged for 3 min at 7200 rpm (4400g)
using a portable centrifuge (StatSpin X3) (powered by
12 V batteries connected to an AC/DC inverter). The
plasma was placed into dry ice (-80), transported to
Australia, stored at -80 and analyzed in duplicate with an
automated chemiluminescence immunoassay (DiaSorin
Liaison, Stillwater, MN, USA) with the Sangtec S100
analysis kit. For some of the participants the level at
2590 m was actually higher than the 3700 m level during
ascent. The 2590 m value followed a fairly rapid ascent
from 1400 to 2590 m (1190 m in 6–8 h) and it is well
recognised that altitude sickness (and therefore potentially
hypoxia induced BBB compromise and S100B level)
relates to the rate of ascent as well as the final altitude
gained. In addition, the 3700 m S100B level followed a
period of rest at 3200 m after which we ascended to the
summit and rested again for 2–3 h prior to the sample
being taken. This summit S100B level may therefore have
reflected a period of acclimatisation. Similarly, the 2590 m
level during descent was taken within a few hours of the
maximal period of hypobaric hypoxia on the summit. It
was therefore deemed appropriate to use a mean of the
three altitudes (2590 and 3700 on ascent, 2590 m on des-
cent) for all subjects. The plasma S100B level was sum-
marised by calculating a mean with 95 % confidence
intervals at baseline and at high altitude.
Student’s t tests for independent or matched samples
were used to compare groups or time points, respectively.
The study has been reviewed and approved by the Royal
Brisbane and Women’s Hospital Human Ethics Research
Committee and carried out according to the National
Statement on Ethical Conduct in Human Research (2007)
produced by the National Health and Medical Research
Council of Australia.
Results
The results from this second ascent are presented and
contrast with the parallel S100B data from the first ascent
for the same 12 people [14]. The results for this current
paper (the second ascent) note that 6 of the 12 participants
were treated with dexamethasone (the ‘treated group’). The
plasma S100B values reduced from 0.183 lg/l (95 % CI
0.083–0.283) at baseline to 0.145 lg/l (95 % CI
0.088–0.202) at altitude for the dexamethasone-treated
group and from 0.147 lg/l (95 % CI 0.022–0.272) at
baseline to 0.133 lg/l (95 % CI 0.085–0.182) at altitude
for the non-treated group (Table 1). The reductions in
S100B between baseline and altitude for this second ascent
were not statistically significant for the treated (p = 0.43)
or non-treated (p = 0.82) groups. There were no significant
differences in plasma S100B levels at either baseline
(p = 0.57) or at altitude (p = 0.70) between the treated or
non-treated groups. Furthermore there was no statistically
significant difference in the baseline plasma S100B level
between the two ascents [all patients p = 0.077, treated
p = 0.22, non-treated p = 0.27]. To summarise the first
ascent S100B results, there was a significant (p\ 0.001)
increase in plasma S100B level from 0.108 lg/l (95 % CI
0.092–0.125) at baseline to 0.216 lg/l (95 % CI
0.165–0.267) at high altitude.
During this ascent there was a statistically significant
decrease in oxygen saturations from baseline to altitude for
both the treated group [baseline 97.3 % (95 % CI
95.9–98.8), at altitude 92.2 % (95 % CI 89.9–94.4),
p = 0.001] and for the non-treated group [baseline 97.8 %
(95 % CI 97.4–98.3) at altitude 92.7 % (95 % CI
90.4–94.9), p = 0.004]. There were no significant differ-
ences at either baseline (p = 0.41) or at altitude (p = 0.70)
in oxygen saturations between the treated and non-treated
groups. There was no statistically significant difference in
the baseline oxygen saturation levels between the two
ascents (all participants p = 0.62, treated p = 0.46,
untreated p = 0.36).
For completeness we compared the incidence of and
S100B levels for AMS and non-AMS subjects. In the first
ascent seven subjects experienced acute mountain sickness.
During the second ascent the incidence of AMS reduced,
affecting only three subjects (one from the dexamethasone
group and two from the non-treated group), indicating that
the process of acclimatisation had occurred. No correlation
between plasma S100B levels and acute mountain sickness
was evident during the first ascent and the same lack of
correlation between S100B and AMS was found for the
second ascent (Table 2). Given that there is no significant
difference in plasma S100B levels between treatments and
insufficient numbers of participants with AMS, compar-
isons were made between AMS and non-AMS sufferers
only. The plasma S100B levels for the three AMS sufferers
changed from 0.100 lg/l (95 % CI -0.029 to 0.229) at
baseline to 0.127 lg/l (95 % CI -0.031 to 0.284) at high
altitude which was marginally significant (p = 0.057)
compared to the non-AMS sufferers who showed a non-
significant (p = 0.35) change from 0.187 lg/l (95 % CI
0.102–0.272) at baseline to 0.143 lg/l (95 % CI
0.108–0.179) at altitude. There was no significant differ-
ence in plasma S100B levels between AMS and non-AMS
groups at baseline (p = 0.23) or at altitude (p = 0.63).
There was no significant difference in oxygen saturations
between AMS and non-AMS participants at baseline
(p = 0.88) or at altitude (p = 0.49). There was no signif-
icant difference between oxygen saturation levels at
Neurol Sci (2016) 37:533–539 535
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baseline between ascents for the non-AMS sufferers
(p = 0.45) and AMS sufferers (p = 81).
Discussion
An elevation of peripheral S100B from baseline following
the hypobaric hypoxia of high altitude has been previously
documented and is thought to represent hypobaric hypoxic
induced opening of the blood–brain barrier [13, 15]. The
statistically significant increase in plasma S100B during
ascent to the same altitude using the same group of vol-
unteers [14] 48 h earlier allows us to comment on the
potential effects of acclimatisation on the BBB when we
compare those S100B levels with this second ascent.
Although an elevation in S100B was not observed in this
(second) ascent during re-exposure to the hypobaric
hypoxia of high altitude for either the non-treated (accli-
matised) or the dexamethasone treated (acclimatised and
dexamethasone) groups, the hypothesis that S100B would
reduce following acclimatisation could not be statistically
confirmed in our study given the wide confidence intervals
and small sample size. A larger study would be required to
confirm these findings.
It would be easier to explain a lack of hypoxia-induced
BBB compromise in our subjects during re-exposure to
hypoxia if higher oxygen saturations were present
compared to the first ascent. The reported improved oxygen
saturations during re-exposure to hypobaric hypoxia [21,
28, 29] did not occur for our participants. The oxygen
saturations at high altitude for the dexamethasone and the
non-dexamethasone group were 92.2 and 92.7 % respec-
tively, compared to 91.6 % for the first ascent, i.e. not
significantly different (all patients p = 0.075, treated
p = 0.36, untreated p = 0.14). Hypothesising on the
mechanism(s) that may be involved in the improved BBB
dysfunction following re-exposure to high altitude, extra-
neous to improved oxygen saturation, is speculative but
may involve cerebral autoregulation, increased chemosen-
sitivity or hypoxic preconditioning. Cerebral autoregula-
tion (CA), the process by which CBF is maintained despite
fluctuations in cerebral perfusion pressure (CPP), is
impaired at high altitude and Subudhi et al. [20] recently
confirmed persistence of dysfunctional CA on re-ascent. A
failure of autoregulation may result in passive cerebral
vasodilatation, a compromised BBB and increased vaso-
genic oedema. The degree of altered autoregulation may
have been less severe 48 h later in our participants result-
ing in an improved BBB relative to the first ascent. A
concept of enhanced hypoxic chemosensitivity has been
suggested which posits that intermittent periods of hypoxia
results in an augmented ventilatory response on re-expo-
sure [30, 31]. A modified ventilation response to hypoxia
or CO2 levels may theoretically adjust the balance of
Table 1 Plasma S100B (lg/l) and oxygen saturations (%) during re-ascent of Mt Fuji (3700 m)
Parameter Group Baseline [mean
(95 % CI)]
Average at altitude
[mean (95 % CI)]
p value between
altitudes
Plasma S100B (lg/l) Treated (n = 6) 0.183 (0.083–0.283) 0.145 (0.088–0.202) 0.43
Nontreated (n = 6) 0.147 (0.022–0.272) 0.133 (0.085–0.182) 0.82
p value between treatments 0.57 0.70
Oxygen saturation (%) Treated (n = 6) 97.3 (95.9–98.8) 92.2 (89.9–94.4) 0.001
Nontreated (n = 6) 97.8 (97.4–98.3) 92.7 (90.4–94.9) 0.004
p value between treatments 0.41 0.70
Treated dexamethasone treated group, nontreated non-dexamethasone group
Table 2 Plasma S100B and oxygen saturations (%) during re-ascent of Mt Fuji (3700 m); comparison of AMS and non-AMS subjects
Parameter Group Baseline [mean
(95 % CI)]
Average at altitude
[mean (95 % CI)]
p value between
altitudes
Plasma S100B (lg/l) AMS (n = 3) 0.100 (0.029–0.229) 0.127 (-0.031 to 0.284) 0.057
Non-AMS (n = 9) 0.187 (0.102–0.272) 0.143 (0.108–0.179) 0.35
p value between treatments 0.23 0.63
Oxygen saturation (%) AMS (n = 3) 97.7 (96.2–99.1) 91.7 (86.5–96.8) 0.059
Non-AMS (n = 9) 97.6 (96.7–98.4) 92.7 (91.0–94.3) \0.001
p value between treatments 0.88 0.49
Treated dexamethasone treated group, nontreated non-dexamethasone group, AMS acute mountain sickness
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hypocapneic vasoconstriction versus hypoxic vasodilata-
tion, local pH and bicarbonate concentrations. These
dynamic processes all of which could potentially alter
arteriolar and capillary vessel calibre and hydrostatic
pressure changes with subsequent effects on the BBB
during hypoxic re-exposure. The activation of specific
genes is an important addition to adaptation to hypoxic
conditions [31] and it may be that downstream gene
products or transcription factors such as hypoxia-inducible-
factor-1 (HIF-1) were still at play 48 h after being switched
on and that an undiscovered mechanism attenuated the
hypoxic induced BBB dysfunction. S100B has known
neuro-protective properties, reducing glutamate excitotoxic
damage [32] and enhancing neurogenesis [33] and the
increased expression of S100B as part of a neuro-protective
response to hypoxia may have been modified by
acclimatisation.
Hypoxic pre-conditioning refers to the phenomenon of
exposure to a moderate hypoxia/ischaemic (HI) insult
providing increased resistance to a subsequent episode of
HI [34, 35]. The first ascent may have acted as hypoxic pre-
conditioning and this may have affected the BBB response
to the second hypobaric hypoxic insult. Wick et al. [36]
report an in vitro model enabling investigation into the
possible molecular mechanisms involved in hypoxic pre-
conditioning. Cerebellar granule neurons (CGN) precon-
ditioned by sub-lethal exposure to reduced oxygen tension
became resistant to successive injuries. The authors report
elevated levels of VEGF and that the activation of VEGF/
VEGF-receptor-2 (VEGFR-2), coupled with Akt/protein
kinase B (PKB) phosphorylation and the subsequent
enhancement of anti-apoptotic proteins may be integral to
the neuroprotection afforded by hypoxic preconditioning.
The enhanced expression of VEGF may also directly affect
BBB permeability by causing loss of tight junction (TJ)
proteins (such as occludin and claudin-5) and subsequent
endothelial barrier disruption [37]. Following hypoxic
injury to the brain the onset of a neuro-inflammatory cas-
cade develops leading to increased release of cytokines,
chemokines, reactive oxygen species and matrix metallo-
proteinases, all of which may cause disruption of the BBB.
Significant protection secondary to hypoxic precondition-
ing in an in vivo model of neonatal HI injury has been
described [38]. The authors report that the underlying
mechanism may involve suppression of pro-inflammatory
gene expression and a reduction in glial cell activation and
the subsequent inflammation following re-exposure to
hypoxia. Furthermore, Tang et al. [39] used a mouse model
to examine the specific genomic response to ischemia
following hypoxic preconditioning and compared this to
gene expression following ischemia alone. They report the
up-regulation of 27 genes mediating diverse function as
sodium homeostasis, aquaporin-4 water channel
expression, stress response and pro-inflammatory genes, all
of which could conceivably affect blood–brain barrier
function in the preconditioned ischemic animals. Many of
these processes may account for the lack of a pronounced
S100B response (potentially reflecting improved BBB
function) during the second hypobaric hypoxic stimulus of
the second ascent.
Our results also allow comment on the potential effects
of dexamethasone on the BBB. A recent meta-analysis has
confirmed the benefit of dexamethasone in the treatment
and prevention of high altitude illnesses [40]. We
hypothesised that dexamethasone would attenuate the
hypobaric hypoxia induced BBB ‘leakiness’ and this would
manifest as a lower S100B level in the dexamethasone
treated group. However, there was no difference in high
altitude plasma S100B level between the dexamethasone
treated (n = 6) and non-treated groups (n = 6), we there-
fore could not confirm an additive effect of the steroid on
attenuating the BBB compromise. An alternative possibil-
ity is that the process of acclimatisation overshadowed any
potential effect of dexamethasone on S100B levels.
For any field study such as this we have to consider the
effect of strenuous exertion on peripheral biomarker levels.
Koh et al. [26] provides a review with some studies cor-
relating elevated S100B levels with exercise while others
did not. During our ascent the strenuous physical exertion
was not associated with an increased S100B discounting
any association. Comparing the S100B levels from the first
ascent to this study we can conclude that if the elevated
plasma S100B level in the first ascent was related to
physical exertion, then a similar rise would be expected
during the second ascent, but this was not observed. Our
subjects were instructed to drink ad libitum reducing any
potential dehydration effects. For completeness we anal-
ysed the S100B data for AMS and non-AMS subjects in the
second ascent (Table 2). These results were in agreement
with the first ascent, i.e. no correlation between AMS and
S100B levels.
This study is open to the criticisms of any field study.
Studies recruiting additional participants, measuring other
biomarkers of BBB (e.g. matrix metalloproteinases) and
the use of a hypoxic chamber with equivalent exercise are
warranted. The effect of dexamethasone (without accli-
matisation) may have been more instructive if we had
repeated the ascent in 6 months, but we were limited by
volunteer availability and funding restrictions. With
hindsight it may have been prudent to combine the results
from both ascents but the increase in S100B with altitude
and the lack of correlation with AMS were important
stand-alone conclusions. Additionally our S100B results
relate to an ascent to 3700 m, and a more severe hypoxic
stimulus (higher altitude) may have facilitated a statistical
difference in the S100B levels between the
Neurol Sci (2016) 37:533–539 537
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dexamethasone treated and non-treated groups. Despite
the limitations, to our knowledge the investigation of
plasma S100B and by extension BBB function during re-
exposure to high altitude, has not been previously
explored. Analysing the molecular response of the BBB to
hypobaric hypoxia and re-exposure to high altitude may
elucidate secondary mechanisms that are common to
many forms of brain injury such as stroke or subarachnoid
haemorrhage.
Conclusion
Our data suggests that the increase in plasma S100B during
the first ascent was not observed in the second ascent for
either the dexamethasone treated or non-treated groups. An
exercise stimulated elevation of plasma S100B levels was
also not observed during the second ascent. The small
sample size and wide confidence intervals precludes any
statistically significant conclusions and a larger study
would be required to confirm these findings.
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